Crown Bioscience Announces U.S. Expansion With New Translational Oncology Center
The newly established center will combine Crown’s existing cardiovascular and metabolic disease (CVMD) services with a new U.S. expansion of Crown oncology services. Crown’s CVMD business features several in vivo models including a unique collection of spontaneously diabetic monkeys. The addition of Crown oncology services will provide U.S.-based pharmaceutical and biotechnology clients’ access to Crown’s distinctive collection of immune-oncology models. The center will enable U.S. based pharmaceutical and biotech partners to improve the selection and development path for promising clinical candidates; reducing drug development costs. The center at the Kannapolis site will also take advantage of state of the art immunology technologies, including flow cytometry and immunoassays, available at DHMRI, and will also be able to access unique mouse strains available in the U.S.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.